01—Abstract
Summary
Summary of the 8-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
International Flavors & Fragrances Inc. filed this Current Report on Form 8-K dated February 20, 2025, to disclose a leadership change under Item 5.02 (Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers).
The Company announced that Simon Herriott, currently President, Health & Biosciences, will leave IFF effective March 31, 2025. The filing states that Mr. Herriott's departure will be treated as a qualifying event under IFF's executive severance policy, meaning his exit triggers the benefits set out in that policy. The filing does not state the amount or terms of any severance payment.
The Company also stated that Leticia Goncalves Lourenço will join IFF effective March 1, 2025, as President of the Health & Biosciences division, so the role is set to be filled by a successor who begins a month before the departing executive's last day. The filing contains no financial results, guidance, or other operational data.
02—Key points
Key Highlights
- Simon Herriott, President, Health & Biosciences, will leave IFF effective March 31, 2025.
- Herriott's departure is treated as a qualifying event under IFF's executive severance policy.
- Leticia Goncalves Lourenço will join IFF effective March 1, 2025, as President of the Health & Biosciences division.
- The successor is scheduled to start on March 1, 2025, before the departing executive's March 31, 2025 exit date, overlapping the transition by one month.
- The filing reports no financial results, guidance, or other financial metrics.
- The 8-K was signed by Jennifer A. Johnson, Executive Vice President, General Counsel and Corporate Secretary, on February 20, 2025.
03—Questions
Frequently Asked Questions
Who is leaving IFF and when?
Simon Herriott, who is currently President, Health & Biosciences, will leave IFF on March 31, 2025, according to the filing.
Who is replacing him?
The filing states that Leticia Goncalves Lourenço will join IFF effective March 1, 2025, as President of the Health & Biosciences division.
Does Herriott's departure trigger severance benefits?
The filing states that his departure will be treated as a qualifying event for purposes of IFF's executive severance policy. It does not disclose the specific amounts or terms of any payments.
Does this filing contain financial results or guidance?
No. The filing covers only the executive leadership change under Item 5.02 and includes no financial results, guidance, or other financial metrics.
04—Continue